Platinum-Resistant Fallopian Tube Carcinoma

Platinum-Resistant Fallopian Tube Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

30 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 5
Ph III recruiting: 1
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03026062	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	completed	Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Aug 5, 2026	clinicaltrials
NCT03206047	Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	completed	Phase 1 / Phase 2	12	National Cancer Institute (NCI)NIH	1	Mar 13, 2025